SCHEMBL4135225

SCHEMBL4135225

CC(C)C[C@@H](CN(CCCCNS(=O)(=O)c1ccc(Cl)cc1Cl)C(=O)Nc1ccc(N(C)C)cc1)NC(=O)Nc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
NPC1 O15118 2/20 0.40
NFKB1 P19838 2/20 0.40
RAB9A P51151 2/20 0.40
NFKB2 Q00653 2/20 0.40
RELA Q04206 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NOX1 Q9Y5S8 1/20 0.40
MAPK1 P28482 2/20 0.38
CCKBR P32239 3/20 0.37
TRPV4 Q9HBA0 2/20 0.36
GAA P10253 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ITGA1 P56199 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4142015 1.00 MAPT (0.40) MAPTNPC1NFKB1RAB9ANFKB2
SCHEMBL4143372 0.95 MAPK1 (0.41) SMN1; SMN2LMNAMAPK1CCKBRTRPV4
SCHEMBL4143367 0.95 MAPK1 (0.41) SMN1; SMN2LMNAMAPK1CCKBRTRPV4
SCHEMBL13872669 0.93 MAPT (0.39) MAPTNPC1NFKB1RAB9ANFKB2
SCHEMBL4127419 0.92 MAPK1 (0.39) MAPK1CCKBRTRPV4GAAITGA1
SCHEMBL4127414 0.92 MAPK1 (0.39) MAPK1CCKBRTRPV4GAAITGA1
SCHEMBL4136390 0.90 MAPK1 (0.40) MEN1KMT2AMAPK1CCKBRTRPV4
SCHEMBL4140598 0.90 MAPK1 (0.40) MEN1KMT2AMAPK1CCKBRTRPV4
SCHEMBL4142787 0.89 MAPK1 (0.42) MAPK1CCKBRTRPV4GAAITGA1
SCHEMBL4142783 0.89 MAPK1 (0.42) MAPK1CCKBRTRPV4GAAITGA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof SMITHKLINE BEECHAM CORPORATION 2009-04-23 US claimed
EP-1940785-A2 ACYCLIC 1,4-DIAMINES AND USES THEREOF SmithKline Beecham Corporation (US) 2008-07-09 EP claimed
WO-2007030761-A2 ACYCLIC 1,4-DIAMINES AND USES THEREOF SMITHKLINE BEECHAM CORPORATION (US) 2007-03-15 WO claimed
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof SMITHKLINE BEECHAM CORPORATION 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof TRPV4, TRPC4, TRPV1 MAPT 2159/4885NPC1 1110/4885NFKB1 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.